RAPT Therapeutics’ (RAPT) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a report issued on Monday morning,Benzinga reports.

Several other research firms have also recently commented on RAPT. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. UBS Group decreased their target price on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research note on Monday, September 9th. Stifel Nicolaus reissued a “hold” rating and issued a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. Wells Fargo & Company reduced their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Finally, Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $8.00 to $2.00 in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.50.

RAPT Therapeutics Trading Up 3.7 %

Shares of RAPT stock opened at $1.12 on Monday. The stock has a 50-day moving average of $1.83 and a 200-day moving average of $2.65. RAPT Therapeutics has a 1-year low of $1.00 and a 1-year high of $27.35. The stock has a market cap of $39.16 million, a price-to-earnings ratio of -0.40 and a beta of 0.33.

RAPT Therapeutics (NASDAQ:RAPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. Sell-side analysts forecast that RAPT Therapeutics will post -2.8 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RAPT. Point72 Asset Management L.P. lifted its holdings in shares of RAPT Therapeutics by 176,725.0% in the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after purchasing an additional 706,900 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of RAPT Therapeutics by 188.7% in the second quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock valued at $2,428,000 after purchasing an additional 520,368 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of RAPT Therapeutics by 4,183.3% in the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after purchasing an additional 456,275 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of RAPT Therapeutics by 21.2% in the first quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock valued at $22,386,000 after purchasing an additional 436,629 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of RAPT Therapeutics by 826.4% in the second quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock valued at $900,000 after purchasing an additional 263,372 shares in the last quarter. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.